Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants
- 30 September 1993
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 95 (3) , 273-278
- https://doi.org/10.1016/0002-9343(93)90279-x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Symptomatic Cytomegalovirus Infection in Renal Transplant Recipients Given Either Minnesota Antilymphoblast Globulin (MALG) or OKT3 for Rejection ProphylaxisAmerican Journal of Kidney Diseases, 1993
- SEQUENTIAL THERAPY—A PROSPECTIVE RANDOMIZED TRIAL OF MALG VERSUS OKT3 FOR PROPHYLACTIC IMMUNOSUPPRESSION IN CADAVER RENAL ALLOGRAFT RECIPIENTSTransplantation, 1992
- A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart TransplantationNew England Journal of Medicine, 1992
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1991
- Options for Prevention of Cytomegalovirus DiseaseAnnals of Internal Medicine, 1991
- The Prevention of Cytomegalovirus Disease in Renal TransplantationAmerican Journal of Kidney Diseases, 1990
- Impact of Cytomegalovirus Infection on Organ Transplant RecipientsClinical Infectious Diseases, 1990
- A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal AllograftsNew England Journal of Medicine, 1989
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987
- Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow TransplantationAnnals of Internal Medicine, 1987